![UMN logo](/assets/logo-14ca9c5bc764343ea0b1ec3edef3d39b15c438f8eb603b1a5fbf826128a74246.png)
StudyFinder
PEPN2113: A Phase 1 and pharmacokinetic study of Uproleselan (GMI-1271, IND #139758, NSC #801708) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that expresses E-selectin ligand on the cell membrane and is in second or greater relapse or that is refractory to relapse therapy
![](/assets/flag-998f631fa7bef54098575ae881e66e71315bfae4a5d1ffb34ab8f527fcff0600.jpg)
Recruiting
A Phase 1 and pharmacokinetic study of Uproleselan (GMI-1271, IND #139758, NSC #801708) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that expresses E-selectin ligand on the cell membrane and is in second or greater relapse or that is refractory to relapse therapy
Male or Female
Up to 18 years old
Inclusion Criteria:
• patient must be enrolled on APAL2020SC (NCT04726241)
• patients must be between 1 and 17 years of age at the time of study enrollment
• patients, with or without Down syndrome (DS), and with de novo acute myeloid leukemia, therapy-related acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that expresses E-selectin ligand on the cell membrane
• second or greater relapse or refractory AML OR refractory myelodysplastic syndrome (MDS) OR mixed phenotype acute leukemia (MPAL)
• see link to clinicaltrials.gov for complete criteria
Exclusion Criteria:
• patients who are currently receiving another investigational drug are not eligible
• patients who are currently receiving other anti-cancer agents are not eligible except patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy
• study staff will review additional exclusion criteria
Cancer, Cancer
AML, Myelodysplastic Syndrome Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia
Allison Fullenkamp - fulle631@umn.edu
Robin Williams
SITE00001697
See this study on ClinicalTrials.gov